{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:57:47Z","timestamp":1786993067596,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jns.2025.123550","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:08:32Z","timestamp":1747422512000},"page":"123550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study"],"prefix":"10.1016","volume":"474","author":[{"given":"Kimiaki","family":"Utsugisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Grimson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2025.123550_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jns.2025.123550_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123550_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","article-title":"Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future","volume":"38","author":"Crisafulli","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2025.123550_bb0020","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2025.123550_bb0025","unstructured":"Zilbrysq US PI, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf. (Accessed: January 2025)."},{"key":"10.1016\/j.jns.2025.123550_bb0030","unstructured":"Zilbrysq EU SmPC, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zilbrysq-epar-product-information_en.pdf. (Accessed: January 2025)."},{"issue":"7","key":"10.1016\/j.jns.2025.123550_bb0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2025.123550_bb0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123550_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/cen3.12766","article-title":"Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: a subgroup analysis of the phaseIII randomized RAISE study","volume":"15","author":"Utsugisawa","year":"2024","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jns.2025.123550_bb0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.123550_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.jns.2025.123550_bb0060","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jns.2025.123550_bb0075","author":"Zilbrysq Japan PI"},{"issue":"5","key":"10.1016\/j.jns.2025.123550_bb0080","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2025.123550_bb0085","series-title":"Plasmapheresis and the Immunobiology of Myasthenia Gravis","first-page":"289","article-title":"High-dose daily prednisone therapy in myasthenia gravis","author":"Sanders","year":"1979"},{"issue":"2","key":"10.1016\/j.jns.2025.123550_bb0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2025.123550_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2025.123550_bb0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mus.27791","article-title":"Treatment patterns in myasthenia gravis: a United States health claims analysis","volume":"67","author":"Mahic","year":"2023","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2025.123550_bb0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2025.123550_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2025.123550_bb0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T10:34:57Z","timestamp":1751193297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"alternative-id":["S0022510X25001674"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123550","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123550"}}